［1］ RAJKUMAR SV.Multiple myeloma:2022 update on diagnosis,risk stratification,and management［J］.Am J Hematol,2022,97(8):1086-1107.
［2］ WANG S,XU L,FENG J,et al.Prevalence and incidence of multiple myeloma in urban area in China:A national population-based analysis［J］.Front Oncol,2019,9:1513.
［3］ 邱录贵.多发性骨髓瘤的发病与国人特点［J］.中国实用内科杂志,2006,26(12):886-888.
QIU LG.The incidence of multiple myeloma and the characteristics of Chinese people［J］.Chinese Journal of Practical Internal Medicine,2006,26(12):886-888.
［4］ MINNIE SA,HILL GR.Immunotherapy of multiple myeloma［J］.J Clin Invest,2020,130(4):1565-1575.
［5］ HUANG J,CHAN SC,LOK V,et al.The epidemiological landscape of multiple myeloma:a global cancer registry estimate of disease burden,risk factors,and temporal trends［J］.Lancet Haematol,2022,9(9):e670-e677.
［6］ LAROCCA A,DOLD SM,ZWEEGMAN S,et al.Patient-centered practice in elderly myeloma patients:an overview and consensus from the European myeloma network(EMN)［J］.Leukemia,2018,32(8):1697-1712.
［7］ JOAO C,GERALDES C,NEVES M,et al.Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice:Deliberations and recommendations from an expert panel of hematologists［J］.J Geriatr Oncol,2020,11(8):1210-1216.
［8］ BONELLO F,BOCCADORO M,LAROCCA A.Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients［J］.Cancers(Basel),2020,12(11)：3106.
［9］ PALUMBO A,BRINGHEN S,MATEOS MV,et al.Geriatric assessment predicts survival and toxicities in elderly myeloma patients:an international myeloma working group report［J］.Blood,2015,125(13):2068-2074.
［10］ XUE R,CHENG L,SONG LM,et al.Evaluation of the efficacy and safety of chemotherapy in elderly patients with multiple myeloma under different frailty scores［J］.Chinese Journal of Experimental Hematology,2022,30(1):170-174.
［11］ YAO Y,SUI WW,LIAO AJ,et al.Comprehensive geriatric assessment in newly diagnosed older myeloma patients:a multicentre,prospective,non-interventional study［J］.Age Ageing,2022,51(1):afab211.
［12］ ZHANG Y,LIANG X,XU W,et al.Individualized dynamic frailty-tailored therapy(DynaFiT) in elderly patients with newly diagnosed multiple myeloma:a prospective study［J］.J Hematol Oncol,2024,17(1):48.
［13］ GROEN K,STEGE C,NASSERINEJAD K,et al.Ixazomib,daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma:an open-label phase 2 trial［J］.EClinicalMedicine,2023,63:102167.
［14］ MINA R,LAROCCA A,OFFIDANI M,et al.Efficacy and safety of ixazomib induction and maintenance in newly diagnosed multiple myeloma patients according to the IMWG frailty score:A post-hoc analysis of the EMN10-unito trial［J］.Blood,2020,136(Supplement 1):44-45.
［15］ BRINGHEN S,POUR L,BENJAMIN R,et al.Ixazomib versus placebo as postinduction maintenance therapy in newly diagnosed multiple myeloma patients:An analysis by age and frailty status of the tourmaline-MM4 study［J］.Clin Lymphoma Myeloma Leuk,2023,23(7):491-504.
［16］ COULSON AB,ROYLE KL,PAWLYN C,et al.Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma FiTNEss(UK-MRA myeloma XIV trial):a study protocol for a randomised phase Ⅲ trial［J］.BMJ Open,2022,12(6):e056147.
［17］ KLEBER M,IHORST G,TERHORST M,et al.Comorbidity as a prognostic variable in multiple myeloma:comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score［J］.Blood Cancer J,2011,1(9):e35.
［18］ ENGELHARDT M,DOLD SM,IHORST G,et al.Geriatric assessment in multiple myeloma patients:validation of the international myeloma working group(IMWG) score and comparison with other common comorbidity scores［J］.Haematologica,2016,101(9):1110-1119.
［19］ GUERARD EJ,DEAL AM,CHANG Y,et al.Frailty index developed from a cancer-specific geriatric assessment and the association with mortality among older adults with cancer［J］.J Natl ComprCanc Netw,2017,15(7):894-902.
［20］ ISAACS A,FIALA M,TUCHMAN S,et al.A comparison of three different approaches to defining frailty in older patients with multiple myeloma［J］.J Geriatr Oncol,2020,11(2):311-315.
［21］ MILANI P,VINCENT RS,MERLINI G,et al.N-terminal fragment of the type-B natriuretic peptide(NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma［J］.Am J Hematol,2016,91(11):1129-1134.
［22］ COOK G,ROYLE KL,PAWLYN C,et al.A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma(UK myeloma research alliance risk profile):a development and validation study［J］.Lancet Haematol,2019,6(3):e154-e166.
［23］ REDDER L,KLAUSEN TW,VANGSTED AJ,et al.Validation of the UK myeloma research alliance risk profile,a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation,a population-based study from the Danish national multiple myeloma registry［J］.Br J Haematol,2020,193(1):119-124.
［24］ FACON T,DIMOPOULOS MA,MEULEMAN N,et al.A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST(MM-020) trial［J］.Leukemia,2020,34(1):224-233.
［25］ VERELST SG,TERMORSHUIZEN F,UYL-DE GC,et al.Effect of thalidomide with melphalan and prednisone on health-related quality of life(HRQoL) in elderly patients with newly diagnosed multiple myeloma:a prospective analysis in a randomized trial［J］.Ann Hematol,2011,90(12):1427-1439.
［26］ CRUZ-JENTOFT AJ,BAHAT G,BAUER J,et al.Sarcopenia:revised European consensus on definition and diagnosis［J］.Age Ageing,2019,48(1):16-31.
［27］ CHAN H,CHONG YH,SEOW MY,et al.Electronic FRAIL score may predict treatment outcomes in older adults with myeloma［J］.J Geriatr Oncol,2021,12(4):515-520.
［28］ CALLANDER NS,BALJEVIC M,ADEKOLA K,et al.NCCN guidelines(R) insights:Multiple myeloma,version 3.2022［J］.J Natl ComprCanc Netw,2022,20(1):8-19.
［29］ MINA R,BRINGHEN S,WILDES TM,et al.Approach to the older adult with multiple myeloma［J］.Am Soc Clin Oncol Educ Book,2019,93(39):500-518.
［30］ DIMOPOULOS MA,MOREAU P,TERPOS E,et al.Multiple myeloma:EHA-ESMO clinical practice guidelines for diagnosis,treatment and follow-up［J］.Hemasphere,2021,5(2):e528.
［31］ KAWEME NM,CHANGWE GJ,ZHOU F.Approaches and challenges in the management of multiple myeloma in the very old:Future treatment prospects［J］.Front Med(Lausanne),2021,8:612696.
［32］ OKAZUKA K,ISHIDA T,NASHIMOTO J,et al.The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma［J］.Eur J Haematol,2020,104(2):110-115.
［33］ FU W,BANG SM,HUANG H,et al.Bortezomib,melphalan,and prednisone with or without daratumumab in transplant-ineligible asian patients with newly diagnosed multiple myeloma:The phase 3 OCTANS study［J］.Clin Lymphoma Myeloma Leuk,2023,23(6):446-455.
［34］ FACON T,COOK G,USMANI SZ,et al.Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma:frailty subgroup analysis of MAIA［J］.Leukemia,2022,36(4):1066-1077.
［35］ DURIE B,HOERING A,SEXTON R,et al.Longer term follow-up of the randomized phase Ⅲ trial SWOG S0777:bortezomib,lenalidomide and dexamethasone vs lenalidomide and dexamethasone in patients(Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant(ASCT)［J］.Blood Cancer J,2020,10(5):53.
［36］ MATEOS MV,CAVO M,BLADE J,et al.Overall survival with daratumumab,bortezomib,melphalan,and prednisone in newly diagnosed multiple myeloma(ALCYONE):a randomised,open-label,phase 3 trial［J］.Lancet,2020,395(10218):132-141.
［37］ LAROCCA A,BONELLO F,GAIDANO G,et al.Dose/schedule-adjusted Rd-R vs continuous Rd for elderly,intermediate-fit patients with newly diagnosed multiple myeloma［J］.Blood,2021,137(22):3027-3036.